Structured Review

Siemens Healthineers hcv rna
Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of <t>HCV</t> <t>RNA.</t> (A) Linear regression analysis of the small-volume RTx assay versus the bDNA assay for 273 specimens. (B) Bland-Altman
Hcv Rna, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hcv rna/product/Siemens Healthineers
Average 92 stars, based on 1 article reviews
Price from $9.99 to $1999.99
hcv rna - by Bioz Stars, 2020-05
92/100 stars

Images

1) Product Images from "Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3? Untranslated Region ▿"

Article Title: Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3? Untranslated Region ▿

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.02170-08

Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of HCV RNA. (A) Linear regression analysis of the small-volume RTx assay versus the bDNA assay for 273 specimens. (B) Bland-Altman
Figure Legend Snippet: Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of HCV RNA. (A) Linear regression analysis of the small-volume RTx assay versus the bDNA assay for 273 specimens. (B) Bland-Altman

Techniques Used:

2) Product Images from "Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3? Untranslated Region ▿"

Article Title: Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3? Untranslated Region ▿

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.02170-08

Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of HCV RNA. (A) Linear regression analysis of the small-volume RTx assay versus the bDNA assay for 273 specimens. (B) Bland-Altman
Figure Legend Snippet: Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of HCV RNA. (A) Linear regression analysis of the small-volume RTx assay versus the bDNA assay for 273 specimens. (B) Bland-Altman

Techniques Used:

3) Product Images from "The Human Fetal Immune Response to Hepatitis C Virus Exposure in Utero"

Article Title: The Human Fetal Immune Response to Hepatitis C Virus Exposure in Utero

Journal: The Journal of Infectious Diseases

doi: 10.1093/infdis/jiq044

HCV-exposed neonates had lower levels of T cell activation than controls. A , Representative flow plots showing the gating strategy for the activation markers CD38 and HLA-DR on CD4 + and CD8 + T cells. B , Scatter plots showing the absolute number of HLA-DR + , CD38 + , and HLA-DR + CD38 + CD4 + T cells ( top panels ) and CD8 + T cells ( bottom panels ). Horizontal lines represent the median. To ensure that the apparent outlier in the HLA-DR + and HLA-DR + CD38 + control data did not exert undue influence on our results, a nonparametric test (Mann-Whitney) was used to calculate P values. The HCV-exposed neonate with a positive cord blood HCV RNA level is indicated by an open triangle (Δ). C , Spearman correlations of the percentage of HLA-DR + Tregs with the percentages of HLA-DR + CD4 + and HLA-DR + CD8 + T cells. HCV-exposed neonates are indicated by open shapes and control neonates by closed shapes.
Figure Legend Snippet: HCV-exposed neonates had lower levels of T cell activation than controls. A , Representative flow plots showing the gating strategy for the activation markers CD38 and HLA-DR on CD4 + and CD8 + T cells. B , Scatter plots showing the absolute number of HLA-DR + , CD38 + , and HLA-DR + CD38 + CD4 + T cells ( top panels ) and CD8 + T cells ( bottom panels ). Horizontal lines represent the median. To ensure that the apparent outlier in the HLA-DR + and HLA-DR + CD38 + control data did not exert undue influence on our results, a nonparametric test (Mann-Whitney) was used to calculate P values. The HCV-exposed neonate with a positive cord blood HCV RNA level is indicated by an open triangle (Δ). C , Spearman correlations of the percentage of HLA-DR + Tregs with the percentages of HLA-DR + CD4 + and HLA-DR + CD8 + T cells. HCV-exposed neonates are indicated by open shapes and control neonates by closed shapes.

Techniques Used: Activation Assay, Flow Cytometry, MANN-WHITNEY

HCV-exposed neonates produced more IFN-γ in response to polyclonal stimulation than controls. A , Representative flow plots showing IFN-γ, TNF-α, and IL-2 production from CD4 + and CD8 + T cells after polyclonal stimulation and intracellular staining. 2.5 × 10 5 fresh cord blood mononuclear cells were stimulated with phorbol 12-myristate 13-acetate (PMA) plus ionomycin for 16 h in the presence of purified anti-CD28, anti-CD49d, and GolgiPlug. All negative control stimulations (media containing DMSO only) had background levels less than .25%. B , Scatter plots showing the aggregate data for cytokine production from CD4 + T cells (top panels) and CD8 + T cells ( bottom panels ) after stimulation with PMA and ionomycin. Horizontal lines represent the median. The HCV-exposed neonate with a positive cord blood HCV RNA level is indicated by an open triangle (Δ). C , Representative flow plots showing the gating strategy for the maturation markers CD45RA and CD27 on CD4 + and CD8 + T cells making IFN-γ. Subsets were defined as follows: naïve (T naïve : CD27 + CD45RA + ), central memory (T CM : CD27 + CD45RA - ), effector memory (T EM : CD27 - CD45RA - ), and terminally differentiated effector (T EMRA : CD27 - CD45RA + ) T cells. Bar graphs show the aggregate data for the maturation subsets within IFN-γ + CD4 + and IFN-γ + CD8 + T cells. Bars show the median and error bars indicate the interquartile range. The bar graph legend indicating the different T cell subsets is shown. In all panels, P values were calculated using the Mann-Whitney test.
Figure Legend Snippet: HCV-exposed neonates produced more IFN-γ in response to polyclonal stimulation than controls. A , Representative flow plots showing IFN-γ, TNF-α, and IL-2 production from CD4 + and CD8 + T cells after polyclonal stimulation and intracellular staining. 2.5 × 10 5 fresh cord blood mononuclear cells were stimulated with phorbol 12-myristate 13-acetate (PMA) plus ionomycin for 16 h in the presence of purified anti-CD28, anti-CD49d, and GolgiPlug. All negative control stimulations (media containing DMSO only) had background levels less than .25%. B , Scatter plots showing the aggregate data for cytokine production from CD4 + T cells (top panels) and CD8 + T cells ( bottom panels ) after stimulation with PMA and ionomycin. Horizontal lines represent the median. The HCV-exposed neonate with a positive cord blood HCV RNA level is indicated by an open triangle (Δ). C , Representative flow plots showing the gating strategy for the maturation markers CD45RA and CD27 on CD4 + and CD8 + T cells making IFN-γ. Subsets were defined as follows: naïve (T naïve : CD27 + CD45RA + ), central memory (T CM : CD27 + CD45RA - ), effector memory (T EM : CD27 - CD45RA - ), and terminally differentiated effector (T EMRA : CD27 - CD45RA + ) T cells. Bar graphs show the aggregate data for the maturation subsets within IFN-γ + CD4 + and IFN-γ + CD8 + T cells. Bars show the median and error bars indicate the interquartile range. The bar graph legend indicating the different T cell subsets is shown. In all panels, P values were calculated using the Mann-Whitney test.

Techniques Used: Produced, Flow Cytometry, Staining, Purification, Negative Control, MANN-WHITNEY

HCV-exposed neonates had lower granzyme and pro-inflammatory cytokine levels than controls. Scatter plots showing the levels of granzyme A, granzyme B, IL-12, IL-17A, and IL-18 determined by multiplex assay, which was performed on plasma from 7 controls and 6 HCV-exposed neonates. Horizontal lines represent the median, and P values were calculated using the Mann-Whitney test. The HCV-exposed neonate with a positive cord blood HCV RNA level is indicated by an open triangle (Δ).
Figure Legend Snippet: HCV-exposed neonates had lower granzyme and pro-inflammatory cytokine levels than controls. Scatter plots showing the levels of granzyme A, granzyme B, IL-12, IL-17A, and IL-18 determined by multiplex assay, which was performed on plasma from 7 controls and 6 HCV-exposed neonates. Horizontal lines represent the median, and P values were calculated using the Mann-Whitney test. The HCV-exposed neonate with a positive cord blood HCV RNA level is indicated by an open triangle (Δ).

Techniques Used: Multiplex Assay, MANN-WHITNEY

HCV-exposed neonates had similar numbers of regulatory T cells (Tregs) as controls but lower levels of HLA-DR + Tregs. A , Representative flow plots showing the gating strategy for Tregs from control and HCV-exposed neonates. The upper panels are gated on CD4 + T lymphocytes and show CD25 + FoxP3 + CD4 + T cells (Tregs). The lower panels show the HLA-DR + subset within Tregs. B , Scatter plots showing the percentage and absolute numbers of Tregs, FoxP3 MFI on Tregs, and percentage of HLA-DR + Tregs for both groups. Horizontal lines represent the median. The HCV-exposed neonate with a positive cord blood HCV RNA level is indicated by an open triangle (Δ). C , The histogram shows the FoxP3 MFI on HLA-DR + Tregs ( filled solid line ) and HLA-DR – Tregs ( open dotted line ) from a representative HCV-exposed neonate. The bar graph shows the aggregate data from all control and HCV-exposed neonates. Bars show the median and error bars indicate the interquartile range. In all panels, P values were calculated using the Mann-Whitney test.
Figure Legend Snippet: HCV-exposed neonates had similar numbers of regulatory T cells (Tregs) as controls but lower levels of HLA-DR + Tregs. A , Representative flow plots showing the gating strategy for Tregs from control and HCV-exposed neonates. The upper panels are gated on CD4 + T lymphocytes and show CD25 + FoxP3 + CD4 + T cells (Tregs). The lower panels show the HLA-DR + subset within Tregs. B , Scatter plots showing the percentage and absolute numbers of Tregs, FoxP3 MFI on Tregs, and percentage of HLA-DR + Tregs for both groups. Horizontal lines represent the median. The HCV-exposed neonate with a positive cord blood HCV RNA level is indicated by an open triangle (Δ). C , The histogram shows the FoxP3 MFI on HLA-DR + Tregs ( filled solid line ) and HLA-DR – Tregs ( open dotted line ) from a representative HCV-exposed neonate. The bar graph shows the aggregate data from all control and HCV-exposed neonates. Bars show the median and error bars indicate the interquartile range. In all panels, P values were calculated using the Mann-Whitney test.

Techniques Used: Flow Cytometry, MANN-WHITNEY

4) Product Images from "Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3? Untranslated Region ▿"

Article Title: Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3? Untranslated Region ▿

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.02170-08

Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of HCV RNA. (A) Linear regression analysis of the small-volume RTx assay versus the bDNA assay for 273 specimens. (B) Bland-Altman
Figure Legend Snippet: Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of HCV RNA. (A) Linear regression analysis of the small-volume RTx assay versus the bDNA assay for 273 specimens. (B) Bland-Altman

Techniques Used:

5) Product Images from "Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification ▿"

Article Title: Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification ▿

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.01300-08

Correlation between HCV RNA levels measured by the m 2000 sp - m 2000 rt platform and bDNA in the same samples from group B, consisting of 141 clinical samples containing HCV genotype 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), and 6 (F). The dotted lines are the equality lines.
Figure Legend Snippet: Correlation between HCV RNA levels measured by the m 2000 sp - m 2000 rt platform and bDNA in the same samples from group B, consisting of 141 clinical samples containing HCV genotype 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), and 6 (F). The dotted lines are the equality lines.

Techniques Used:

HCV RNA quantification of a commercial standard panel containing 5 × 10 1 (1.7 log 10 ) to 5 × 10 6 (6.7 log 10 ) HCV RNA IU/ml (OptiQuant HCV RNA; AcroMetrix, Benicia, CA) by the m 2000 sp - m 2000 rt platform (top) and bDNA (bottom). The average measured results are shown as a function of the expected results (solid lines). The dotted lines are the equality lines.
Figure Legend Snippet: HCV RNA quantification of a commercial standard panel containing 5 × 10 1 (1.7 log 10 ) to 5 × 10 6 (6.7 log 10 ) HCV RNA IU/ml (OptiQuant HCV RNA; AcroMetrix, Benicia, CA) by the m 2000 sp - m 2000 rt platform (top) and bDNA (bottom). The average measured results are shown as a function of the expected results (solid lines). The dotted lines are the equality lines.

Techniques Used:

Correlation between HCV RNA levels measured by CAP/CTM and bDNA (left) and by the m 2000 sp - m 2000 rt platform and bDNA (right) (A), and in CAP/CTM and the m 2000 sp - m 2000 rt platform (B) in the same samples from group C, consisting of 35 clinical samples containing HCV genotypes 1 to 5. The dotted lines are the equality lines.
Figure Legend Snippet: Correlation between HCV RNA levels measured by CAP/CTM and bDNA (left) and by the m 2000 sp - m 2000 rt platform and bDNA (right) (A), and in CAP/CTM and the m 2000 sp - m 2000 rt platform (B) in the same samples from group C, consisting of 35 clinical samples containing HCV genotypes 1 to 5. The dotted lines are the equality lines.

Techniques Used:

(A) Bland-Altman plot analysis of HCV RNA levels measured by both the m 2000 sp - m 2000 rt platform and bDNA in the 141 samples from group B. The difference between HCV RNA levels measured by the m 2000 sp - m 2000 rt platform and bDNA is represented as a function of the mean of the two values. Different genotypes are represented by different colors. The gray area corresponds to the mean difference ± 1.96 SD. (B) Distribution of the differences between HCV RNA levels measured in the m 2000 sp - m 2000 rt platform and bDNA in the same samples according to the HCV genotype (1 to 5). The results are presented as box plots, where the horizontal line represents the median value, the gray boxes the 50th percentiles, and the upper and lower bars the 95th percentiles.
Figure Legend Snippet: (A) Bland-Altman plot analysis of HCV RNA levels measured by both the m 2000 sp - m 2000 rt platform and bDNA in the 141 samples from group B. The difference between HCV RNA levels measured by the m 2000 sp - m 2000 rt platform and bDNA is represented as a function of the mean of the two values. Different genotypes are represented by different colors. The gray area corresponds to the mean difference ± 1.96 SD. (B) Distribution of the differences between HCV RNA levels measured in the m 2000 sp - m 2000 rt platform and bDNA in the same samples according to the HCV genotype (1 to 5). The results are presented as box plots, where the horizontal line represents the median value, the gray boxes the 50th percentiles, and the upper and lower bars the 95th percentiles.

Techniques Used:

6) Product Images from "The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA"

Article Title: The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.02004-12

Deming correlation and Bland-Altman plot analyses of HCV RNA levels determined by bDNA, CAP/CTM HCV, and CAP/CTM HCV v2.0 in 122 clinical samples (group A) containing different subtypes of HCV genotype 4. (A) Deming regression of CAP/CTM HCV versus bDNA. (B) Bland-Altman plots of CAP/CTM HCV versus bDNA. (C) Deming regression of CAP/CTM HCV v.2.0 versus bDNA. (D) Bland-Altman plots of CAP/CTM HCV v2.0 versus bDNA. (E) Deming regression of CAP/CTM HCV v2.0 versus CAP/CTM HCV. (F) Bland-Altman plots of CAP/CTM HCV v2.0 versus CAP/CTM HCV. In the Deming regression figures, the dashed line is the identity line; the black line surrounded by two dashed lines shows the Deming fit and 95% confidence interval, respectively. In the Bland-Altman figures, the difference between the HCV RNA levels obtained by the two assays is plotted as a function of the mean of the two values; the gray area and numbers correspond to the mean difference ± 1.96 standard deviation.
Figure Legend Snippet: Deming correlation and Bland-Altman plot analyses of HCV RNA levels determined by bDNA, CAP/CTM HCV, and CAP/CTM HCV v2.0 in 122 clinical samples (group A) containing different subtypes of HCV genotype 4. (A) Deming regression of CAP/CTM HCV versus bDNA. (B) Bland-Altman plots of CAP/CTM HCV versus bDNA. (C) Deming regression of CAP/CTM HCV v.2.0 versus bDNA. (D) Bland-Altman plots of CAP/CTM HCV v2.0 versus bDNA. (E) Deming regression of CAP/CTM HCV v2.0 versus CAP/CTM HCV. (F) Bland-Altman plots of CAP/CTM HCV v2.0 versus CAP/CTM HCV. In the Deming regression figures, the dashed line is the identity line; the black line surrounded by two dashed lines shows the Deming fit and 95% confidence interval, respectively. In the Bland-Altman figures, the difference between the HCV RNA levels obtained by the two assays is plotted as a function of the mean of the two values; the gray area and numbers correspond to the mean difference ± 1.96 standard deviation.

Techniques Used: Standard Deviation

Related Articles

Sequencing:

Article Title: The Human Fetal Immune Response to Hepatitis C Virus Exposure in Utero
Article Snippet: .. HCV antibody status was determined by immunoassay (Siemens Healthcare Diagnostics), HCV RNA by the VERSANT HCV RNA 3.0 Assay (Siemens Healthcare Diagnostics), and HCV genotype by sequencing of the 5′ UTR (ARUP Laboratories). ..

Amplification:

Article Title: Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?
Article Snippet: .. Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosuppression are potentially at risk of HBV reactivation. .. Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosuppression are potentially at risk of HBV reactivation.

other:

Article Title: Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification ▿
Article Snippet: In the Versant HCV RNA 3.0 Assay, HCV RNA was recovered from 50 μl of serum and quantified in the semiautomated System 340 bDNA analyzer (Siemens Medical Solutions Diagnostics, Tarrytown, NY), according to the manufacturer's instructions.

Article Title: The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA
Article Snippet: In the Versant HCV RNA 3.0 assay, HCV RNA was recovered from 50 μl of serum or plasma and quantified by the semiautomated system 340 bDNA analyzer (Siemens Medical Solutions Diagnostics), according to the manufacturer's instructions.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Siemens Healthineers siemens versant hcv rna version 1 0
    Treatment outcomes for SOF/LDV without RBV for <t>HCV</t> genotype 1 (1a, 1b, or nonsubtyped 1) in treatment‐naive, patients without cirrhosis who had an HCV <t>RNA</t>
    Siemens Versant Hcv Rna Version 1 0, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/siemens versant hcv rna version 1 0/product/Siemens Healthineers
    Average 92 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    siemens versant hcv rna version 1 0 - by Bioz Stars, 2020-05
    92/100 stars
      Buy from Supplier

    85
    Siemens Healthineers hcv rna positive plasma
    (A) Mean ± SD <t>HCV</t> viral load (log 10 IU/ml) at baseline and after storage at −20°C tested using the Versant HCV <t>RNA</t> 3.0 (bDNA) assay and CAP-CTM assay; (B) mean ± SD HCV viral load (log 10 IU/ml) at baseline and after storage
    Hcv Rna Positive Plasma, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcv rna positive plasma/product/Siemens Healthineers
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcv rna positive plasma - by Bioz Stars, 2020-05
    85/100 stars
      Buy from Supplier

    85
    Siemens Healthineers versant hcv rna qualitative test
    Scatter plot of log 10 core antigen concentration (fmol/liter) and <t>RNA</t> concentration (IU/ml) determined in 385 samples by the Architect <t>HCV</t> Ag and Versant HCV RNA 3.0 (bDNA) assays, respectively. The correlation coefficient and conversion equation given in the inset were calculated by nonparametric Passing/Bablok regression analysis.
    Versant Hcv Rna Qualitative Test, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/versant hcv rna qualitative test/product/Siemens Healthineers
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    versant hcv rna qualitative test - by Bioz Stars, 2020-05
    85/100 stars
      Buy from Supplier

    Image Search Results


    Treatment outcomes for SOF/LDV without RBV for HCV genotype 1 (1a, 1b, or nonsubtyped 1) in treatment‐naive, patients without cirrhosis who had an HCV RNA

    Journal: Hepatology (Baltimore, Md.)

    Article Title: All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings

    doi: 10.1002/hep.29814

    Figure Lengend Snippet: Treatment outcomes for SOF/LDV without RBV for HCV genotype 1 (1a, 1b, or nonsubtyped 1) in treatment‐naive, patients without cirrhosis who had an HCV RNA

    Article Snippet: Real‐time PCR assays for the quantification of HCV RNA included Roche COBAS AmpliPrep/COBAS TaqMan HCV (Roche Molecular Systems, Pleasanton, CA; lower limit of detection, 15 IU/mL), Abbott RealTime HCV assay (Abbott Laboratories, Abbott Park, IL; lower limit of detection, 12 IU/mL), or Siemens Versant HCV RNA version 1.0 (Siemens Healthcare GmbH, Erlangen, Germany; lower limit of detection, 15 IU/mL).

    Techniques:

    Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of HCV RNA. (A) Linear regression analysis of the small-volume RTx assay versus the bDNA assay for 273 specimens. (B) Bland-Altman

    Journal: Journal of Clinical Microbiology

    Article Title: Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3? Untranslated Region ▿

    doi: 10.1128/JCM.02170-08

    Figure Lengend Snippet: Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of HCV RNA. (A) Linear regression analysis of the small-volume RTx assay versus the bDNA assay for 273 specimens. (B) Bland-Altman

    Article Snippet: The 200 clinical specimens from Dynacare Laboratories consisted of 179 specimens with measurable HCV RNA by the bDNA assay and 21 specimens without detectable HCV RNA by the bDNA assay, with HCV genotypes 1a ( n = 65), 1b ( n = 21), 2 ( n = 4), and 3 ( n = 7) determined for 97 of the HCV RNA-positive specimens by the Trugene HCV 5′NC genotyping kit (Trugene; Siemens Healthcare Diagnostics Inc.).

    Techniques:

    (A) Mean ± SD HCV viral load (log 10 IU/ml) at baseline and after storage at −20°C tested using the Versant HCV RNA 3.0 (bDNA) assay and CAP-CTM assay; (B) mean ± SD HCV viral load (log 10 IU/ml) at baseline and after storage

    Journal: Journal of Clinical Microbiology

    Article Title: Stability of Hepatitis C Virus, HIV, and Hepatitis B Virus Nucleic Acids in Plasma Samples after Long-Term Storage at -20oC and -70oC ▿

    doi: 10.1128/JCM.02447-10

    Figure Lengend Snippet: (A) Mean ± SD HCV viral load (log 10 IU/ml) at baseline and after storage at −20°C tested using the Versant HCV RNA 3.0 (bDNA) assay and CAP-CTM assay; (B) mean ± SD HCV viral load (log 10 IU/ml) at baseline and after storage

    Article Snippet: Thirty-five HCV RNA-positive plasma samples were tested using the Siemens Versant HCV RNA, version 3.0 (Versant HCV RNA 3.0) branched DNA [bDNA]) assay (Siemens Healthcare Diagnostics, Tarrytown, NY) and stored at −20°C for 1 year.

    Techniques:

    (A) Mean ± SD HIV RNA load (log 10 number of copies/ml) at baseline and after storage at −20°C for 2.3 years using the Versant HCV RNA 3.0 (bDNA) test; (B) mean ± SD HIV RNA load (log 10 number of copies/ml) at baseline and

    Journal: Journal of Clinical Microbiology

    Article Title: Stability of Hepatitis C Virus, HIV, and Hepatitis B Virus Nucleic Acids in Plasma Samples after Long-Term Storage at -20oC and -70oC ▿

    doi: 10.1128/JCM.02447-10

    Figure Lengend Snippet: (A) Mean ± SD HIV RNA load (log 10 number of copies/ml) at baseline and after storage at −20°C for 2.3 years using the Versant HCV RNA 3.0 (bDNA) test; (B) mean ± SD HIV RNA load (log 10 number of copies/ml) at baseline and

    Article Snippet: Thirty-five HCV RNA-positive plasma samples were tested using the Siemens Versant HCV RNA, version 3.0 (Versant HCV RNA 3.0) branched DNA [bDNA]) assay (Siemens Healthcare Diagnostics, Tarrytown, NY) and stored at −20°C for 1 year.

    Techniques:

    (A) Mean ± SD HBV DNA load (log 10 IU/ml) at baseline and after storage at −20°C for up to 5 years tested using the CAP-CTM assay and the Versant HCV RNA 3.0 (bDNA) test; (B) mean ± SD HBV DNA load (log 10 IU/ml) at baseline

    Journal: Journal of Clinical Microbiology

    Article Title: Stability of Hepatitis C Virus, HIV, and Hepatitis B Virus Nucleic Acids in Plasma Samples after Long-Term Storage at -20oC and -70oC ▿

    doi: 10.1128/JCM.02447-10

    Figure Lengend Snippet: (A) Mean ± SD HBV DNA load (log 10 IU/ml) at baseline and after storage at −20°C for up to 5 years tested using the CAP-CTM assay and the Versant HCV RNA 3.0 (bDNA) test; (B) mean ± SD HBV DNA load (log 10 IU/ml) at baseline

    Article Snippet: Thirty-five HCV RNA-positive plasma samples were tested using the Siemens Versant HCV RNA, version 3.0 (Versant HCV RNA 3.0) branched DNA [bDNA]) assay (Siemens Healthcare Diagnostics, Tarrytown, NY) and stored at −20°C for 1 year.

    Techniques:

    Scatter plot of log 10 core antigen concentration (fmol/liter) and RNA concentration (IU/ml) determined in 385 samples by the Architect HCV Ag and Versant HCV RNA 3.0 (bDNA) assays, respectively. The correlation coefficient and conversion equation given in the inset were calculated by nonparametric Passing/Bablok regression analysis.

    Journal: Journal of Clinical Microbiology

    Article Title: Analytical Performance Characteristics and Clinical Utility of a Novel Assay for Total Hepatitis C Virus Core Antigen Quantification ▿

    doi: 10.1128/JCM.01640-09

    Figure Lengend Snippet: Scatter plot of log 10 core antigen concentration (fmol/liter) and RNA concentration (IU/ml) determined in 385 samples by the Architect HCV Ag and Versant HCV RNA 3.0 (bDNA) assays, respectively. The correlation coefficient and conversion equation given in the inset were calculated by nonparametric Passing/Bablok regression analysis.

    Article Snippet: The Versant HCV RNA qualitative test (a transcription-mediated amplification [TMA] assay) ( ) and the Versant HCV RNA 3.0 assay (a branched DNA [bDNA] assay) ( ) (both available from Siemens Diagnostics, Eschborn, Germany) were used to amplify HCV RNA isothermally and to establish the HCV RNA concentration by use of the bDNA technology, respectively.

    Techniques: Concentration Assay

    Huh 7 cells stably transfected with an AD78-based HCV full-length construct were treated for 48 h with alpha interferon (A) or the protease inhibitor BILN 2061 (B). The impact of this antiviral therapy on in vitro HCV replication was monitored by determination of both the core antigen and the RNA concentrations. The values shown are the means ± SDs of three replicates and are expressed as a percentage relative to the results for nontreated cells.

    Journal: Journal of Clinical Microbiology

    Article Title: Analytical Performance Characteristics and Clinical Utility of a Novel Assay for Total Hepatitis C Virus Core Antigen Quantification ▿

    doi: 10.1128/JCM.01640-09

    Figure Lengend Snippet: Huh 7 cells stably transfected with an AD78-based HCV full-length construct were treated for 48 h with alpha interferon (A) or the protease inhibitor BILN 2061 (B). The impact of this antiviral therapy on in vitro HCV replication was monitored by determination of both the core antigen and the RNA concentrations. The values shown are the means ± SDs of three replicates and are expressed as a percentage relative to the results for nontreated cells.

    Article Snippet: The Versant HCV RNA qualitative test (a transcription-mediated amplification [TMA] assay) ( ) and the Versant HCV RNA 3.0 assay (a branched DNA [bDNA] assay) ( ) (both available from Siemens Diagnostics, Eschborn, Germany) were used to amplify HCV RNA isothermally and to establish the HCV RNA concentration by use of the bDNA technology, respectively.

    Techniques: Stable Transfection, Transfection, Construct, Protease Inhibitor, In Vitro